This is on the eve of their interim P2 data release mid April. I wonder if cu6 has at least time til just prior to the release of their dose expansion cohort. This isn't accounting for bombesin either m
hopefully, the SP will rise and there is more competition between BP.
eli lily, Novartis, AZ and BMS have all made plays... hopefully there is more than 1 BP keen on cu6 if it ends up much better than pluvicto.
Research/Valuation, page-231
-
- There are more pages in this discussion • 309 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add CU6 (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$6.46 |
Change
0.090(1.41%) |
Mkt cap ! $2.013B | |||
| Open | High | Low | Value | Volume |
| $6.40 | $6.50 | $6.13 | $10.02M | 1.580M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 3329 | $6.43 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $6.50 | 45351 | 7 |
View Market Depth
| Last trade - 16.10pm 24/07/2024 (20 minute delay) ? |
| CU6 (ASX) Chart |